
DENTSPLY SIRONA (XRAY) Stock Forecast & Price Target
DENTSPLY SIRONA (XRAY) Analyst Ratings
Bulls say
Dentsply Sirona has experienced a modest increase in sales, with reported growth of 2.8% in Europe and notable contributions from Wellspect Healthcare, which achieved $81 million in revenue, reflecting an 8.6% increase. The firm's potential upside is bolstered by improving market conditions for implants, market share gains in clear aligners, and overall margin enhancements that may drive faster earnings per share (EPS) growth. Additionally, growth in the SureSmile segment showcases robust expansion, particularly in Europe, indicating effective execution and successful new product launches that contribute positively to the company’s overall outlook.
Bears say
Dentsply Sirona's financial performance revealed significant challenges, as the adjusted earnings per share (EPS) of $0.26 fell considerably short of the expected $0.43, primarily due to a substantial revenue loss attributed to the Byte product shutdown. The company faced an 8.3% decline in revenue from its connected technology solutions (CTS) segment, compounded by increasing operating expenses and lower gross margins, which negatively impacted overall profitability. Additionally, revenue within the orthodontics segment suffered a high-double-digit decline, further indicating vulnerability and raising concerns regarding future growth prospects amidst ongoing restructuring initiatives.
This aggregate rating is based on analysts' research of DENTSPLY SIRONA and is not a guaranteed prediction by Public.com or investment advice.
DENTSPLY SIRONA (XRAY) Analyst Forecast & Price Prediction
Start investing in DENTSPLY SIRONA (XRAY)
Order type
Buy in
Order amount
Est. shares
0 shares